For patients not currently prescribed methylnaltrexone AND for patients currently prescribed methylnaltrexone, non-formulary methylnaltrexone tablets (Relistor®) will be covered on the prescription drug benefit when the following criteria are met:

- Diagnosis of opioid induced constipation in an adult with an active opioid prescription
  -AND-
- Prescribed by an Oncologist, or a Hospice/Palliative Care clinician for a patient currently enrolled in Hospice or Palliative Care program, or after consultation with a Pain Management Specialist.
  -AND-
- Patient has failed a trial of at least 2 weeks or has an intolerance or contraindication to scheduled dosing of the following medications, used in combination with other agent(s) with different mechanism of action^ and route of administration:
  - polyethylene glycol (MiraLAX),
  - lactulose or sorbitol,
  - senna,
  - bisacodyl

Laxatives should be used in combination regularly to be effective in management of opioid-induced constipation.
  -AND-
- Inadequate response or intolerance to:
  - naldemedine (Symproic) (preferred non-formulary option)
  - naloxegol (Movantik) AND
  - lubiprostone (Amitiza)

(all are non-formulary, criteria-based prescribed drugs)

^ e.g. osmotic with stimulant (polyethylene glycol and senna and/or bisacodyl suppository)